Dr. Wolpaw’s laboratory seeks to develop an understanding of how tumor heterogeneity and epigenetics impact inflammatory signaling and immunotherapy responses in pediatric solid tumors with a goal of developing more efficacious, less toxic therapies to treat these devastating diseases.
